CA2319123A1 - A pharmaceutical preparation comprising an angiotensin ii type 2 receptor agonist, and use thereof - Google Patents

A pharmaceutical preparation comprising an angiotensin ii type 2 receptor agonist, and use thereof Download PDF

Info

Publication number
CA2319123A1
CA2319123A1 CA002319123A CA2319123A CA2319123A1 CA 2319123 A1 CA2319123 A1 CA 2319123A1 CA 002319123 A CA002319123 A CA 002319123A CA 2319123 A CA2319123 A CA 2319123A CA 2319123 A1 CA2319123 A1 CA 2319123A1
Authority
CA
Canada
Prior art keywords
agonist
angiotensin
type
receptor
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002319123A
Other languages
English (en)
French (fr)
Inventor
Anders Pettersson
Lars Fandriks
Anders Hallberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacore AB
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2319123A1 publication Critical patent/CA2319123A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002319123A 1998-02-24 1999-02-24 A pharmaceutical preparation comprising an angiotensin ii type 2 receptor agonist, and use thereof Abandoned CA2319123A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9800550-7 1998-02-24
SE9800550A SE9800550D0 (sv) 1998-02-24 1998-02-24 A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
PCT/SE1999/000262 WO1999043339A1 (en) 1998-02-24 1999-02-24 A pharmaceutical preparation comprising an angiotensin ii type 2 receptor agonist, and use thereof

Publications (1)

Publication Number Publication Date
CA2319123A1 true CA2319123A1 (en) 1999-09-02

Family

ID=20410283

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002319123A Abandoned CA2319123A1 (en) 1998-02-24 1999-02-24 A pharmaceutical preparation comprising an angiotensin ii type 2 receptor agonist, and use thereof

Country Status (18)

Country Link
EP (1) EP1066048A1 (no)
JP (1) JP2002504516A (no)
KR (1) KR20010041211A (no)
CN (1) CN1291104A (no)
AU (1) AU755949B2 (no)
BR (1) BR9908188A (no)
CA (1) CA2319123A1 (no)
EE (1) EE200000481A (no)
HU (1) HUP0101411A3 (no)
ID (1) ID26639A (no)
IL (1) IL137990A0 (no)
IS (1) IS5594A (no)
MX (1) MXPA00008172A (no)
NO (1) NO20004215L (no)
NZ (1) NZ506188A (no)
SE (1) SE9800550D0 (no)
SK (1) SK11522000A3 (no)
WO (1) WO1999043339A1 (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001043761A2 (en) * 1999-12-16 2001-06-21 University Of Southern California Methods for treating and preventing damage to mucosal tissue
US6821953B1 (en) 1999-12-16 2004-11-23 University Of Southern California Methods for treating and preventing damage to mucosal tissue
ATE372987T1 (de) 2001-05-31 2007-09-15 Vicore Pharma Ab Trizyklische verbindungen, nützlich als angiotensin ii agonisten
CN101193886B (zh) 2005-04-12 2014-08-27 维科尔药物公司 三环的血管紧张素ii激动剂
EP1869024B1 (en) 2005-04-12 2010-11-10 Vicore Pharma AB New tricyclic angiotensin ii agonists
ES2582945T3 (es) 2005-04-12 2016-09-16 Vicore Pharma Ab Nuevos agonistas bicíclicos de angiotensina II
CA2631491C (en) * 2005-12-14 2015-02-24 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
US8835471B2 (en) 2010-06-11 2014-09-16 Vicore Pharma Ab Use of angiotensin II agonists
EP2455388A1 (en) 2010-11-23 2012-05-23 LanthioPep B.V. Novel angiotensin type 2 (AT2) receptor agonists and uses thereof.
US20150119329A1 (en) * 2012-04-16 2015-04-30 New York University Modulation of angiotensin ii receptors for the prevention and treatment of malaria cerebral
WO2016139475A1 (en) 2015-03-02 2016-09-09 Vicore Pharma Ab Angiotensin ii receptor agonist for treating pulmonary fibrosis
WO2017221012A1 (en) 2016-06-21 2017-12-28 Vicore Pharma Ab Methods and compositions for preventing or reducing the risk of cancer treatment-related cardiotoxicity
GB201818164D0 (en) 2018-11-07 2018-12-19 Vicore Pharma Ab New composition
CN114514032A (zh) 2019-08-02 2022-05-17 兰提欧派普有限公司 用于治疗癌症的血管紧张素2型(at2)受体激动剂
GB201913603D0 (en) 2019-09-20 2019-11-06 Vicore Pharma Ab New compounds
JP2023518948A (ja) 2020-03-19 2023-05-09 ヴィコール ファルマ アーベー アンギオテンシンｉｉに関連する疾患、障害又は状態の治療及び／又は予防に有用な新規化合物
GB202004094D0 (en) 2020-03-20 2020-05-06 Vicore Pharma Ab New compounds and uses
GB202006079D0 (en) 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
GB202006081D0 (en) 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
GB202006074D0 (en) 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
GB202013721D0 (en) 2020-09-01 2020-10-14 Vicore Pharma Ab New compounds
GB202104038D0 (en) 2021-03-23 2021-05-05 Vicore Pharma Ab New compounds
GB202104033D0 (en) 2021-03-23 2021-05-05 Vicore Pharma Ab New compounds
JP2024511453A (ja) 2021-03-23 2024-03-13 ヴィコール ファルマ アーベー 選択的アンジオテンシンｉｉ受容体リガンド
CA3222721A1 (en) 2021-07-09 2023-01-12 Nadia Nasser PETERSEN New selective angiotensin ii compounds
GB202115303D0 (en) 2021-10-25 2021-12-08 Vicore Pharma Ab New formulation
GB202201723D0 (en) 2022-02-10 2022-03-30 Vicore Pharma Ab New use
WO2023152503A1 (en) 2022-02-10 2023-08-17 Vicore Pharma Ab Use of buloxibutid for the treatment of idiopathic pulmonary fibrosis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5444067A (en) * 1993-08-30 1995-08-22 Merck & Co., Inc. Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety
AU3708295A (en) * 1994-11-04 1996-05-31 Stefan L. Marklund Use of receptor agonists to stimulate superoxide dismutase activity
SE9501881D0 (sv) * 1995-05-19 1995-05-19 Astra Ab New pharmacological use of AII-receptor antagonists
US5834432A (en) * 1995-06-06 1998-11-10 The University Of Southern California Use of angiotensin II Type 2 receptor agonists in tissue repair
SE9502219D0 (sv) * 1995-06-19 1995-06-19 Astra Ab Novel medical use

Also Published As

Publication number Publication date
BR9908188A (pt) 2000-10-24
AU755949B2 (en) 2003-01-02
EE200000481A (et) 2002-02-15
MXPA00008172A (es) 2002-06-21
KR20010041211A (ko) 2001-05-15
NO20004215L (no) 2000-09-18
EP1066048A1 (en) 2001-01-10
IL137990A0 (en) 2001-10-31
NO20004215D0 (no) 2000-08-23
WO1999043339A1 (en) 1999-09-02
SK11522000A3 (sk) 2001-04-09
NZ506188A (en) 2003-04-29
ID26639A (id) 2001-01-25
SE9800550D0 (sv) 1998-02-24
IS5594A (is) 2000-08-21
AU2753799A (en) 1999-09-15
JP2002504516A (ja) 2002-02-12
CN1291104A (zh) 2001-04-11
HUP0101411A3 (en) 2002-11-28
HUP0101411A2 (hu) 2002-03-28

Similar Documents

Publication Publication Date Title
AU755949B2 (en) A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
Steranka et al. Antagonists of B2 bradykinin receptors
EP1789067B1 (en) Use of growth hormone secretagogues for stimulating the motility of the gastrointestinal system
Sakaguchi et al. Inhibition of tissue angiotensin converting enzyme. Quantitation by autoradiography.
KR101456151B1 (ko) 고양이에서 전신성 질환을 치료하기 위한 안지오텐신 ｉｉ 수용체 길항제
Naesdal et al. Effect of omeprazole, a substituted benzimidazole, on 24-h intragastric acidity in patients with peptic ulcer disease
Ferrario et al. Advances in the renin angiotensin system: focus on angiotensin-converting enzyme 2 and angiotensin-(1–7)
Khalil et al. VIP modulates substance P-induced plasma extravasation in vivo
CA2590804C (en) Use of bombesin/gastrin-releasing peptide antagonist for the treatment of sepsis, acute lung injury, septic shock or rheumatoid arthritis
Sharma et al. Pharmacologic targets and prototype therapeutics in the kallikrein-kinin system: bradykinin receptor agonists or antagonists
Kirkegaard et al. Exocrine secretion of epidermal growth factor from Brunner's glands. Stimulation by VIP and acetylcholine
Stöckmann et al. Long-term treatment of patients with endocrine gastrointestinal tumours with the somatostatin analogue SMS 201-995
Jenkins et al. Somatostatin in the treatment of non-variceal upper gastrointestinal bleeding
Farthing Octreotide in the treatment of refractory diarrhoea and intestinal fistulae.
D'Amato et al. Cholecystokinin-A receptor antagonists: therapies for gastrointestinal disorders
Warzecha et al. Calcitonin gene-related peptide can attenuate or augment pancreatic damage in caerulein-induced pancreatitis in rats
Bursztyn et al. Effects of a novel renin inhibitor in patients with essential hypertension
Waisman et al. Naloxone is protective against indomethacin-induced intestinal ulceration in the rat
Herzig et al. Regulation of the action of the novel cholecystokinin-releasing peptide diazepam binding inhibitor by inhibitory hormones and taurocholate
Shionoiri et al. Pharmacokinetics and depressor effect of delapril in patients with essential hypertension
Evangelista et al. Cysteamine induced-duodenal ulcers are associated with a selective depletion in gastric and duodenal calcitonin gene-related peptide-like immunoreactivity in rats
CZ20003080A3 (cs) Farmaceutický prostředek obsahující agonistu receptoru pro angiotensin II 2.typu a jeho použití
Nussberger et al. Chronic treatment of hypertensive patients with converting enzyme inhibitors
Brunner et al. The clinical application of converting enzyme inhibitors
Miller et al. The kallikrein-kinin-kininogen system

Legal Events

Date Code Title Description
FZDE Discontinued